India, Nov. 19 -- Johnson & Johnson (JNJ) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), seeking approval of CAPLYTA (lumateperone) for the treatment of manic or mixed episodes associated with bipolar I disorder in adults.

The application is supported by two positive Phase 3 studies showing that once-daily CAPLYTA 42 mg significantly reduced manic symptoms compared with placebo. Improvement was observed as early as Day 3 and remained sustained through Week 3.

Phase 3 Studies Show Rapid Improvement

The pivotal Study 451 and Study 452 were randomized, double-blind, placebo-controlled trials evaluating CAPLYTA against placebo in adults experiencing manic episodes, w...